PABAF (Patrys) Debt-to-Asset : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Patrys Debt-to-Asset?

Patrys's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $ Mil. Patrys's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $ Mil. Patrys's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $7.69 Mil. Patrys's debt to asset for the quarter that ended in Jun. 2026 was 0.00.

Patrys  (OTCPK:PABAF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Patrys Debt-to-Asset Related Terms

Patrys Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Patrys's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Patrys Debt-to-Asset Chart

Patrys Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -

Patrys Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -

PABAF vs VRTX, REGN, MRNA: Debt-to-Asset Comparison

For the Biotechnology subindustry, Patrys's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Patrys Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Patrys's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Patrys's Debt-to-Asset falls into.


Patrys Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Patrys's Debt-to-Asset for the fiscal year that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=( + ) / 7.6878069232
=0.00

Patrys's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=( + ) / 7.6878069232
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Patrys Business Description

Other Exchanges PABDA:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3000
Patrys Ltd is a biopharmaceutical company focused on developing novel antibody-based therapies prominently for cancer and related inflammatory diseases. Its core technology platform involves antibodies that penetrate cell nuclei and inhibit cancer cell DNA repair mechanisms. The company advances therapeutic candidates from its antibody platforms, including ones licensed from Yale University, with ongoing preclinical and clinical development activities. Patrys generates revenue through licensing agreements and collaborations linked to its antibody technologies. Its operations and development efforts span Australia and the United States.